Merck KGaA (MKGAF) inks a second collaboration deal with Beijing-based BeiGene.
The new deal is a licensing, development, and commercialization agreement for BeiGene-290, a preclinical PARP inhibitor.
The terms of the agreement call for German Merck to take on the development and commercialization responsibilities for '290 outside of China.
Milestone payments to BeiGene could reach $232M.
BeiGene also received an undisclosed upfront payment. (PR)